Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Despite more than 2 decades of research, an effective vaccine that can prevent HIV-1 infection in populations exposed to the virus remains elusive. In the pursuit of an HIV-1 vaccine, does prevention of exposure to maternal HIV-1 in utero, at birth or in early life through breast milk require special consideration? This article reviews what is known about the immune mechanisms of susceptibility and resistance to mother-to-child transmission (MTCT) of HIV-1 and summarizes studies that have used passive or active immunization strategies to interrupt MTCT of HIV-1. Potentially modifiable infectious cofactors that may enhance transmission and/or disease progression (especially in the developing world) are described. An effective prophylactic vaccine against HIV-1 infection needs to be deployed as part of the Extended Program of Immunization recommended by the World Health Organization for use in developing countries, so it is important to understand how the infant immune system responds to HIV-1 antigens, both in natural infection and presented by candidate vaccines.

Original publication

DOI

10.1016/j.clp.2010.08.005

Type

Journal article

Journal

Clin Perinatol

Publication Date

12/2010

Volume

37

Pages

787 - ix

Keywords

Clinical Trials as Topic, Drug Industry, Female, HIV Infections, HIV-1, Helminthiasis, Herpes Genitalis, Herpesvirus 2, Human, Humans, Immunization, Passive, Infant, Newborn, Infectious Disease Transmission, Vertical, Malaria, Pregnancy, Vaccination, Vaginosis, Bacterial, Viral Vaccines